Zacks Investment Research upgraded shares of PAREXEL International Corporation (NASDAQ:PRXL) from a hold rating to a buy rating in a research note issued to investors on Thursday. Zacks Investment Research currently has $98.00 price objective on the medical research company’s stock.

According to Zacks, “Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. “

A number of other research firms have also weighed in on PRXL. BidaskClub lowered PAREXEL International Corporation from a strong-buy rating to a buy rating in a research note on Friday, July 28th. Mizuho increased their price objective on PAREXEL International Corporation from $66.00 to $75.00 and gave the company a buy rating in a research note on Tuesday, May 30th. Barclays PLC lowered PAREXEL International Corporation from an overweighr rating to an equal weight rating and set a $87.00 price objective for the company. in a research note on Tuesday, June 20th. Jefferies Group LLC reissued a hold rating and set a $88.10 price objective on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Finally, Raymond James Financial, Inc. raised PAREXEL International Corporation from an underperform rating to a mkt perform rating in a research note on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. PAREXEL International Corporation currently has an average rating of Hold and a consensus target price of $75.93.

PAREXEL International Corporation (NASDAQ PRXL) remained flat at $87.89 during midday trading on Thursday. The company had a trading volume of 556,752 shares. PAREXEL International Corporation has a one year low of $51.16 and a one year high of $87.93. The company’s 50 day moving average price is $87.57 and its 200 day moving average price is $76.06. The firm has a market capitalization of $4.46 billion, a P/E ratio of 42.67 and a beta of 0.79.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The business had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. During the same period last year, the business earned $0.94 earnings per share. On average, analysts expect that PAREXEL International Corporation will post $3.89 EPS for the current year.

WARNING: “PAREXEL International Corporation (PRXL) Upgraded by Zacks Investment Research to “Buy”” was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/parexel-international-corporation-prxl-upgraded-by-zacks-investment-research-to-buy/1536524.html.

A number of institutional investors have recently made changes to their positions in the stock. World Asset Management Inc raised its position in shares of PAREXEL International Corporation by 0.3% in the second quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock valued at $279,000 after buying an additional 9 shares in the last quarter. 1st Global Advisors Inc. increased its position in shares of PAREXEL International Corporation by 0.4% in the second quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock valued at $469,000 after buying an additional 21 shares during the last quarter. Amalgamated Bank increased its position in shares of PAREXEL International Corporation by 0.6% in the second quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock valued at $631,000 after buying an additional 42 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in shares of PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after buying an additional 73 shares during the last quarter. Finally, Meadow Creek Investment Management LLC increased its position in shares of PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock valued at $125,000 after buying an additional 132 shares during the last quarter. 87.49% of the stock is owned by institutional investors and hedge funds.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Analyst Recommendations for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.